Literature DB >> 19589876

Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene.

Kristine C Olson1, Ryan W Dellinger, Qing Zhong, Dongxiao Sun, Shantu Amin, Thomas E Spratt, Philip Lazarus.   

Abstract

The UDP-glucuronosyltransferase (UGT) 1A9 has been shown to play an important role in the detoxification of several carcinogens and clearance of anticancer and pain medications. The goal of the present study was to identify novel polymorphisms in UGT1A9 and characterize their effect on glucuronidation activity. The UGT1A9 gene was analyzed by direct sequencing of buccal cell genomic DNA from 90 healthy subjects. In addition to a previously identified single nucleotide polymorphism (SNP) at codon 33 resulting in an amino acid substitution (Met>Thr), two low-prevalence (<0.02) novel missense SNPs at codons 167 (Val>Ala) and 183 (Cys>Gly) were identified and are present in both white and African-American subjects. Glucuronidation activity assays using HEK293 cell lines overexpressing wild-type or variant UGT1A9 demonstrated that the UGT1A9(33Thr) and UGT1A9(183Gly) variants exhibited differential glucuronidation activities compared with wild-type UGT1A9, but this was substrate-dependent. The UGT1A9(167Ala) variant exhibited levels of activity similar to those of wild-type UGT1A9 for all substrates tested. Whereas the wild-type and UGT1A9(33Thr) and UGT1A9(167Ala) variants formed homodimers as determined by Western blot analysis of native polyacrylamide gels, the UGT1A9(183Gly) variant was incapable of homodimerization. These results suggest that several low-prevalence missense polymorphisms exist for UGT1A9 and that two of these (M33T and C183G) are functional. These results also suggest that although Cys183 is necessary for UGT1A9 homodimerization, the lack of capacity for UGT1A9 homodimerization is not sufficient to eliminate UGT1A9 activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589876      PMCID: PMC2769039          DOI: 10.1124/dmd.108.024596

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  39 in total

Review 1.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Metabolic gene polymorphism frequencies in control populations.

Authors:  S Garte; L Gaspari; A K Alexandrie; C Ambrosone; H Autrup; J L Autrup; H Baranova; L Bathum; S Benhamou; P Boffetta; C Bouchardy; K Breskvar; J Brockmoller; I Cascorbi; M L Clapper; C Coutelle; A Daly; M Dell'Omo; V Dolzan; C M Dresler; A Fryer; A Haugen; D W Hein; A Hildesheim; A Hirvonen; L L Hsieh; M Ingelman-Sundberg; I Kalina; D Kang; M Kihara; C Kiyohara; P Kremers; P Lazarus; L Le Marchand; M C Lechner; E M van Lieshout; S London; J J Manni; C M Maugard; S Morita; V Nazar-Stewart; K Noda; Y Oda; F F Parl; R Pastorelli; I Persson; W H Peters; A Rannug; T Rebbeck; A Risch; L Roelandt; M Romkes; D Ryberg; J Salagovic; B Schoket; J Seidegard; P G Shields; E Sim; D Sinnet; R C Strange; I Stücker; H Sugimura; J To-Figueras; P Vineis; M C Yu; E Taioli
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-12       Impact factor: 4.254

Review 3.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

Authors:  J B Houston; K E Kenworthy
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

4.  Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.

Authors:  Aleksandra Galetin; Stephen E Clarke; J Brian Houston
Journal:  Drug Metab Dispos       Date:  2002-12       Impact factor: 3.922

5.  Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk.

Authors:  Z Zheng; J Y Park; C Guillemette; S P Schantz; P Lazarus
Journal:  J Natl Cancer Inst       Date:  2001-09-19       Impact factor: 13.506

6.  Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications.

Authors:  S S Ghosh; B S Sappal; G V Kalpana; S W Lee; J R Chowdhury; N R Chowdhury
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

7.  Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes.

Authors:  Jia-Long Fang; Frederick A Beland; Daniel R Doerge; Doris Wiener; Chantal Guillemette; M Matilde Marques; Philip Lazarus
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

8.  O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9.

Authors:  Q Ren; S E Murphy; Z Zheng; P Lazarus
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

9.  Key amino acid residues responsible for the differences in substrate specificity of human UDP-glucuronosyltransferase (UGT)1A9 and UGT1A8.

Authors:  Ryoichi Fujiwara; Miki Nakajima; Hiroyuki Yamanaka; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2008-10-02       Impact factor: 3.922

10.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).

Authors:  Jean-François Gagné; Valerie Montminy; Patrick Belanger; Kim Journault; Genevieve Gaucher; Chantal Guillemette
Journal:  Mol Pharmacol       Date:  2002-09       Impact factor: 4.436

View more
  12 in total

1.  Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity.

Authors:  Nathan R Jones; Dongxiao Sun; Willard M Freeman; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2012-06-01       Impact factor: 4.030

2.  Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.

Authors:  Baojian Wu; Xiaoqiang Wang; Shuxing Zhang; Ming Hu
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

3.  Species and inter-individual differences in metabolic capacity of di(2-ethylhexyl)phthalate (DEHP) between human and mouse livers.

Authors:  Yuki Ito; Michihiro Kamijima; Chie Hasegawa; Masahiro Tagawa; Toshio Kawai; Mio Miyake; Yumi Hayashi; Hisao Naito; Tamie Nakajima
Journal:  Environ Health Prev Med       Date:  2013-09-28       Impact factor: 3.674

4.  Alterations in hepatic mRNA expression of phase II enzymes and xenobiotic transporters after targeted disruption of hepatocyte nuclear factor 4 alpha.

Authors:  Hong Lu; Frank J Gonzalez; Curtis Klaassen
Journal:  Toxicol Sci       Date:  2010-10-08       Impact factor: 4.849

5.  Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.

Authors:  Dongxiao Sun; Nathan R Jones; Andrea Manni; Philip Lazarus
Journal:  Cancer Prev Res (Phila)       Date:  2013-05-16

6.  Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences.

Authors:  Ryan W Dellinger; Angela M Gomez Garcia; Frank L Meyskens
Journal:  Drug Metab Pharmacokinet       Date:  2013-08-20       Impact factor: 3.614

7.  Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility.

Authors:  Ryan T Bushey; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

8.  Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism.

Authors:  Ryan T Bushey; Douglas F Dluzen; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2012-10-18       Impact factor: 3.922

9.  Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population.

Authors:  Oliwia Zakerska; Marzena Skrzypczak-Zielinska; Adam Mikstacki; Barbara Tamowicz; Bianka Malengowska; Marlena Szalata; Ryszard Slomski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-11-25       Impact factor: 2.441

10.  Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities.

Authors:  Yan-Qing Liu; Ling-Min Yuan; Zhang-Zhao Gao; Yong-Sheng Xiao; Hong-Ying Sun; Lu-Shan Yu; Su Zeng
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.